Sentiment-Signal
7,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 29.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compe |
| 25.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compe |
| 07.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nce in such filing. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 11.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Appointment of Certain Officers On July 7, 2025, Christopher Stevens was appointed by Rocket Pharmaceuticals, |
| 29.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 07.04.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Appointment of Certain Officers On April 7, 2025, Sarbani Chaudhuri was appointed by Rocket Pharmaceuticals, |
| 28.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compe |
| 05.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compe |
| 11.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compe |
| 29.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 13.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compe |
| 04.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
Stammdaten
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Unternehmen & Branche
| Name | ROCKET PHARMACEUTICALS, INC. |
|---|---|
| Ticker | RCKT |
| CIK | 0001281895 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 373,7 Mio. USD |
| Beta | 0,57 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -223,123,000 | -2.01 | 330,449,000 | 277,221,000 |
| 2025-09-30 | 10-Q | 0 | -50,332,000 | -0.45 | 368,033,000 | 313,669,000 |
| 2025-06-30 | 10-Q | 0 | -68,919,000 | -0.62 | 420,979,000 | 354,211,000 |
| 2025-03-31 | 10-Q | 0 | -61,334,000 | -0.56 | 471,066,000 | 412,138,000 |
| 2024-12-31 | 10-K | 0 | -258,746,000 | -2.73 | 527,700,000 | 463,234,000 |
| 2024-09-30 | 10-Q | 0 | -66,719,000 | -0.71 | 393,688,000 | 329,771,000 |
| 2024-06-30 | 10-Q | 0 | -69,646,000 | -0.74 | 446,411,000 | 384,635,000 |
| 2024-03-31 | 10-Q | 0 | -62,054,000 | -0.66 | 499,442,000 | 441,502,000 |
| 2023-12-31 | 10-K | 0 | -245,595,000 | -2.92 | 566,341,000 | 492,574,000 |
| 2023-09-30 | 10-Q | 0 | -61,899,000 | -0.75 | 598,762,000 | 541,086,000 |
| 2023-06-30 | 10-Q | 0 | -65,701,000 | -0.82 | 461,781,000 | 402,970,000 |
| 2023-03-31 | 10-Q | 0 | -58,335,000 | -0.73 | 514,757,000 | 458,876,000 |
| 2022-12-31 | 10-K | 0 | -221,863,000 | -3.26 | 551,807,000 | 489,686,000 |
| 2022-09-30 | 10-Q | 0 | -57,756,000 | -0.87 | 417,265,000 | 367,313,000 |
| 2022-06-30 | 10-Q | 0 | -54,402,000 | -0.83 | 431,852,000 | 387,696,000 |
| 2022-03-31 | 10-Q | 0 | -42,982,000 | -0.67 | 460,150,000 | 417,620,000 |
| 2021-12-31 | 10-K | 0 | -169,069,000 | -2.67 | 497,020,000 | 454,724,000 |
| 2021-09-30 | 10-Q | 0 | -50,118,000 | -0.79 | 530,241,000 | 485,658,000 |
| 2021-06-30 | 10-Q | 0 | -34,525,000 | -0.55 | 535,154,000 | 489,437,000 |
| 2021-03-31 | 10-Q | 0 | -40,179,000 | -0.65 | 576,484,000 | 479,999,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Wilson Martin | Officer, General Counsel | Open Market Sale | -1,376 | 3.34 | -4,593.09 | -30,9% | |
| 2026-02-18 | Militello John | Officer, See Remarks | Open Market Sale | -1,157 | 3.34 | -3,862.07 | -26,0% | |
| 2026-02-18 | Shah Gaurav | Officer, CEO | Open Market Sale | -5,990 | 3.34 | -19,994.62 | -134,5% | |
| 2026-02-13 | Wilson Martin | Officer, General Counsel | Open Market Sale | -12,253 | 3.31 | -40,581.94 | -272,9% | |
| 2026-02-13 | Militello John | Officer, See Remarks | Open Market Sale | -3,726 | 3.31 | -12,340.51 | -83,0% | |
| 2026-02-13 | Shah Gaurav | Officer, CEO | Open Market Sale | -12,279 | 3.31 | -40,668.05 | -273,5% | |
| 2026-01-02 | Bjork Elisabeth | Director | Open Market Purchase | 10,000 | 3.44 | 34,400.00 | +231,3% | |
| 2025-11-18 | Schwartz Jonathan David | Officer, See Remarks | Open Market Sale | -2,545 | 2.98 | -7,591.74 | -51,1% | |
| 2025-11-18 | Wilson Martin | Officer, General Counsel | Open Market Sale | -1,646 | 2.98 | -4,910.02 | -33,0% | |
| 2025-11-18 | Militello John | Officer, See Remarks | Open Market Sale | -1,086 | 2.98 | -3,239.54 | -21,8% | |
| 2025-11-18 | Shah Gaurav | Director, Officer, CEO | Open Market Sale | -6,276 | 2.98 | -18,721.31 | -125,9% | |
| 2025-10-14 | Militello John | Officer, See Remarks | Open Market Sale | -3,005 | 3.97 | -11,929.85 | -80,2% | |
| 2025-10-14 | Militello John | Officer, See Remarks | Open Market Sale | -558 | 3.98 | -2,218.05 | -14,9% | |
| 2025-10-14 | Militello John | Officer, See Remarks | Open Market Sale | -19,841 | 3.96 | -78,570.36 | -528,4% | |
| 2025-10-14 | Militello John | Officer, See Remarks | Open Market Sale | -5,514 | 3.97 | -21,863.01 | -147,0% | |
| 2025-08-27 | Bjork Elisabeth | Director | Open Market Purchase | 10,000 | 3.41 | 34,100.00 | +229,3% | |
| 2025-08-19 | Schwartz Jonathan David | Officer, See Remarks | Open Market Sale | -805 | 3.00 | -2,411.78 | -16,2% | |
| 2025-08-19 | Militello John | Officer, See Remarks | Open Market Sale | -361 | 3.00 | -1,081.56 | -7,3% | |
| 2025-08-19 | Wilson Martin | Officer, General Counsel | Open Market Sale | -588 | 3.00 | -1,761.65 | -11,8% | |
| 2025-08-18 | Wilson Martin | Officer, General Counsel | Open Market Sale | -1,004 | 3.07 | -3,077.26 | -20,7% | |
| 2025-08-18 | Schwartz Jonathan David | Officer, See Remarks | Open Market Sale | -1,680 | 3.07 | -5,149.20 | -34,6% | |
| 2025-08-18 | Militello John | Officer, See Remarks | Open Market Sale | -699 | 3.07 | -2,142.44 | -14,4% | |
| 2025-08-14 | Wilson Martin | Officer, General Counsel | Open Market Sale | -12,109 | 3.02 | -36,557.07 | -245,8% | |
| 2025-08-14 | Militello John | Officer, See Remarks | Open Market Sale | -7,043 | 3.02 | -21,262.82 | -143,0% | |
| 2025-08-14 | Schwartz Jonathan David | Officer, See Remarks | Open Market Sale | -11,161 | 3.02 | -33,695.06 | -226,6% | |
| 2025-07-03 | Ondrey Aaron | Officer, Chief Financial Officer | Open Market Sale | -1,477 | 2.88 | -4,256.71 | -28,6% | |
| 2025-05-20 | Shah Gaurav | Director, Officer, CEO | Open Market Sale | -2,253 | 6.45 | -14,522.84 | -97,7% | |
| 2025-05-20 | Schwartz Jonathan David | Officer, See Remarks | Open Market Sale | -801 | 6.45 | -5,163.25 | -34,7% | |
| 2025-05-20 | Patel Kinnari | Officer, See Remarks | Open Market Sale | -767 | 6.45 | -4,944.08 | -33,2% | |
| 2025-05-20 | Wilson Martin | Officer, General Counsel | Open Market Sale | -587 | 6.45 | -3,783.80 | -25,4% | |
| 2025-05-20 | Militello John | Officer, See Remarks | Open Market Sale | -357 | 6.45 | -2,301.22 | -15,5% | |
| 2025-05-16 | Schwartz Jonathan David | Officer, See Remarks | Open Market Sale | -1,582 | 6.53 | -10,327.30 | -69,5% | |
| 2025-05-16 | Patel Kinnari | Officer, See Remarks | Open Market Sale | -1,409 | 6.53 | -9,197.95 | -61,9% | |
| 2025-05-16 | Wilson Martin | Officer, General Counsel | Open Market Sale | -946 | 6.53 | -6,175.49 | -41,5% | |
| 2025-05-16 | Militello John | Officer, See Remarks | Open Market Sale | -655 | 6.53 | -4,275.84 | -28,8% | |
| 2025-05-16 | Shah Gaurav | Director, Officer, CEO | Open Market Sale | -3,621 | 6.53 | -23,637.89 | -159,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.